GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

GLP-1 drugs, or GLP-1 receptor agonists ... Switzerland and Japan. What does it do? Victoza is a medicine primarily used to treat type 2 diabetes, by increasing the amount of insulin released. How is ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Discover the unexpected health benefits of diabetes and weight loss medications like Ozempic and Wegovy. Find out how these ...

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.